Blood test hopes to predict immunotherapy success in liver cancer
NCT ID NCT05044676
First seen Dec 24, 2025 · Last updated May 19, 2026 · Updated 16 times
Summary
This study aimed to see if certain immune cells in the blood could help predict which patients with advanced liver cancer would respond to a combination of immunotherapy drugs (Atezolizumab and Bevacizumab). Researchers planned to measure these cells before and after treatment in about 4 participants. The study was terminated early, so the results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Service hépato-gastroentérologie, Hôpital la Pitié-Salpêtrière
Paris, France, 75013, France
Conditions
Explore the condition pages connected to this study.